"Gabexate/pharmacology"[MeSH] - Search Results

Year	Number of Results
1991	12
1992	12
1993	9
1994	5
1995	7
1996	9
1997	9
1998	10
1999	3
2000	2
2001	10
2002	9
2003	18
2004	12
2005	8
2006	10
2007	11
2008	8
2009	7
2010	12
2011	8
2012	10
2013	5
2014	7
2015	9
2016	4
2017	3
2018	1
2019	1
2020	10
2021	1
2022	2
2023	3
2024	1

1

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. Hoffmann M, et al. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5. Cell. 2020. PMID: 32142651 Free PMC article.

2

Systematic skepticism.

Galley HF. Galley HF. Crit Care Med. 2003 Apr;31(4):1284-5. doi: 10.1097/01.CCM.0000060006.78033.D7. Crit Care Med. 2003. PMID: 12682510 No abstract available.

3

Acute pancreatitis.

Famularo G, Minisola G, De Simone C. Famularo G, et al. N Engl J Med. 2006 Aug 31;355(9):961; author reply 961. doi: 10.1056/NEJMc061618. N Engl J Med. 2006. PMID: 16943414 No abstract available.

4

Mechanisms of NMDA receptor inhibition by nafamostat, gabexate and furamidine.

Zhigulin AS, Barygin OI. Zhigulin AS, et al. Eur J Pharmacol. 2022 Mar 15;919:174795. doi: 10.1016/j.ejphar.2022.174795. Epub 2022 Feb 3. Eur J Pharmacol. 2022. PMID: 35122868

5

TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?

Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. Stopsack KH, et al. Cancer Discov. 2020 Jun;10(6):779-782. doi: 10.1158/2159-8290.CD-20-0451. Epub 2020 Apr 10. Cancer Discov. 2020. PMID: 32276929 Free PMC article. Review.

6

Learning from our immunological history: What can SARS-CoV teach us about SARS-CoV-2?

Henrickson SE. Henrickson SE. Sci Immunol. 2020 Apr 3;5(46):eabb8618. doi: 10.1126/sciimmunol.abb8618. Sci Immunol. 2020. PMID: 32245885

7

The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer.

Mollica V, Rizzo A, Massari F. Mollica V, et al. Future Oncol. 2020 Sep;16(27):2029-2033. doi: 10.2217/fon-2020-0571. Epub 2020 Jul 13. Future Oncol. 2020. PMID: 32658591 Free PMC article. No abstract available.

8

[Treatment of disseminated intravascular coagulation].

Koyama T. Koyama T. Rinsho Ketsueki. 2010 Jan;51(1):52-6. Rinsho Ketsueki. 2010. PMID: 20134140 Review. Japanese. No abstract available.

9

[Recent therapeutic strategy for disseminated intravascular coagulation].

Wada H, Matsumoto T, Yamashita Y. Wada H, et al. Rinsho Ketsueki. 2014 Jan;55(1):75-82. Rinsho Ketsueki. 2014. PMID: 24492040 Review. Japanese. No abstract available.

10

Effects of bioactive agents on biliary motor function.

Woods CM, Mawe GM, Shaffer EA, Toouli J, T P Saccone G. Woods CM, et al. Curr Gastroenterol Rep. 2003 Apr;5(2):154-9. doi: 10.1007/s11894-003-0085-8. Curr Gastroenterol Rep. 2003. PMID: 12631457 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

233 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Results by year